Skip to content

The effect of EMLA cream on pain severity of enoxaparin sodium injection

The effect of EMLA cream on pain severity of enoxaparin sodium injection in patients with acute coronary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013012112212N1
Enrollment
76
Registered
2013-03-18
Start date
2012-09-27
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Angina pectoris. Condition 2: Acute myocardial infarction. Angina pectoris Acute myocardial infarction

Interventions

Intervention 1: EMLA cream, 5mg tube , 1 gr ,60 min befor injection ,application 2inches of priumbilical area(overally two grams secound and theird days of study) 2inches of priumbilical area. Interve
Treatment - Drugs
Placebo
EMLA cream, 5mg tube , 1 gr ,60 min befor injection ,application 2inches of priumbilical area(overally two grams secound and theird days of study) 2inches of priumbilical area.
almond hand and face cream, Made in iran,1 gr each times 60 min before injection(overally two grams secound and theird days of study) 2inches of priumbilical area

Sponsors

Mashhad University of Medical Science(MUMS)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Having consent for participation in the study?being informed to person, place and time? Having the least reading and writing ability? haven't Associated diseases that can affect patient pain assessment (delirium, dementia or severe depression, severe visual and hearing impairment, moderate-to-severe diabetic neuropathy) ?Be able to speak the Persian language. Exclusion criteria: Having any tendency for participation to the study? having a noncontinuous infusion of sedative medication such as: Midazolam? receiving of palliative drugs 2 hours before the injection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Injection pain severity. Timepoint: 60 min. Method of measurement: numerical rating scale (NRS).

Secondary

MeasureTime frame
Fatigue. Timepoint: exactly before the injection. Method of measurement: fatigue siverity measurement visual scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Asghar Jesmi

Mashhad University of medical science (MUMS)

jesmiaa891@mums.ac.ir+98 51 1859 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026